投资者 - Sironax

维泰瑞隆NAMPT激活剂SIR4156的II期FORGE-LM肥胖症试验完成约50%患者入组

2026年10月13日

2026年10月5日

Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026

2026年9月16日

维泰瑞隆宣布其脑部递送平台收购选择权已获行使并完成交易

2026年9月16日

维泰瑞隆宣布其脑部递送平台收购选择权已获行使并完成交易

科研发表

Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy adults and elderly participants

Clin Transl Sci., 2025

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants

Clin Transl Sci., 2024

Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy volunteers with therapeutic potential for neurodegenerative diseases

International Neurology & Brain Disorders Conference, 2024

Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial

Journal of Intensive Medicine, 2024